FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128517665> ?p ?o ?g. }

• W2128517665 endingPage "1215" @default.
• W2128517665 startingPage "1208" @default.
• W2128517665 abstract "<h3>Objectives</h3> To investigate the possible role of baseline plasma tumour necrosis factor alpha levels (baseline-TNF) on the clinical response to infliximab in patients with rheumatoid arthritis (RA). <h3>Methods</h3> Patients with RA refractory to methotrexate received 3, 6, or 10 mg/kg of infliximab every 8 weeks, in a randomised, double-blind manner: the RISING study. Clinical response (disease activity score in 28 joints based on C-reactive protein or American College of Rheumatology core set) at week 54 and serum infliximab levels were compared in three patient groups with low, intermediate, or high baseline-TNF (TNF-low, TNF-int, or TNF-high). <h3>Results</h3> In TNF-low patients, the clinical response to different doses of infliximab was comparable, whereas TNF-int patients exhibited a dose-dependent trend. In contrast, TNF-high patients (approximately 13% of the total patients) had a clinical response to 10 mg/kg significantly better than the response to 3 and 6 mg/kg of infliximab. In TNF-high patients, the median trough serum levels of infliximab were below the detection limit (<0.1 μg/ml) at 3 and 6 mg/kg but were greater than 2 μg/ml at 10 mg/kg, whereas the levels were approximately 1 μg/ml for each dosage group in TNF-low patients. <h3>Conclusion</h3> In patients with RA, baseline-TNF is significantly associated with the clinical response to infliximab in patients with a high baseline-TNF. A higher dose of infliximab may be necessary in these patients, whereas lower doses of infliximab are sufficient for those with a low baseline-TNF. Baseline-TNF may be a useful measure for personalising the treatment of RA using infliximab." @default.
• W2128517665 created "2016-06-24" @default.
• W2128517665 creator A5053803963 @default.
• W2128517665 creator A5057335320 @default.
• W2128517665 creator A5060247604 @default.
• W2128517665 creator A5075196043 @default.
• W2128517665 creator A5077855569 @default.
• W2128517665 creator A5083044716 @default.
• W2128517665 creator A5083314956 @default.
• W2128517665 date "2011-04-08" @default.
• W2128517665 modified "2023-10-01" @default.
• W2128517665 title "Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis" @default.
• W2128517665 cites W1953573634 @default.
• W2128517665 cites W1986148335 @default.
• W2128517665 cites W1988572067 @default.
• W2128517665 cites W1994065448 @default.
• W2128517665 cites W1995037940 @default.
• W2128517665 cites W1996472975 @default.
• W2128517665 cites W1996794055 @default.
• W2128517665 cites W1999777294 @default.
• W2128517665 cites W2006831045 @default.
• W2128517665 cites W2013493693 @default.
• W2128517665 cites W2015993259 @default.
• W2128517665 cites W2019737992 @default.
• W2128517665 cites W2023976647 @default.
• W2128517665 cites W2025317527 @default.
• W2128517665 cites W2036047236 @default.
• W2128517665 cites W2046859225 @default.
• W2128517665 cites W2050154180 @default.
• W2128517665 cites W2053691719 @default.
• W2128517665 cites W2060943696 @default.
• W2128517665 cites W2085096893 @default.
• W2128517665 cites W2085411350 @default.
• W2128517665 cites W2093843257 @default.
• W2128517665 cites W2097148639 @default.
• W2128517665 cites W2098279921 @default.
• W2128517665 cites W2111713621 @default.
• W2128517665 cites W2114013630 @default.
• W2128517665 cites W2116591571 @default.
• W2128517665 cites W2120601477 @default.
• W2128517665 cites W2122735365 @default.
• W2128517665 cites W2124853228 @default.
• W2128517665 cites W2130698927 @default.
• W2128517665 cites W2131882149 @default.
• W2128517665 cites W2134069361 @default.
• W2128517665 cites W2139411131 @default.
• W2128517665 cites W2141171232 @default.
• W2128517665 cites W2145573746 @default.
• W2128517665 cites W2146002757 @default.
• W2128517665 cites W2154716537 @default.
• W2128517665 cites W2156260986 @default.
• W2128517665 cites W2159106700 @default.
• W2128517665 cites W2162676235 @default.
• W2128517665 cites W2164005229 @default.
• W2128517665 cites W2166396307 @default.
• W2128517665 cites W2168419457 @default.
• W2128517665 cites W2230942416 @default.
• W2128517665 cites W2319957449 @default.
• W2128517665 cites W2336420290 @default.
• W2128517665 cites W2342129036 @default.
• W2128517665 cites W3146223861 @default.
• W2128517665 doi "https://doi.org/10.1136/ard.2011.153023" @default.
• W2128517665 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3103666" @default.
• W2128517665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21478189" @default.
• W2128517665 hasPublicationYear "2011" @default.
• W2128517665 type Work @default.
• W2128517665 sameAs 2128517665 @default.
• W2128517665 citedByCount "129" @default.
• W2128517665 countsByYear W21285176652012 @default.
• W2128517665 countsByYear W21285176652013 @default.
• W2128517665 countsByYear W21285176652014 @default.
• W2128517665 countsByYear W21285176652015 @default.
• W2128517665 countsByYear W21285176652016 @default.
• W2128517665 countsByYear W21285176652017 @default.
• W2128517665 countsByYear W21285176652018 @default.
• W2128517665 countsByYear W21285176652019 @default.
• W2128517665 countsByYear W21285176652020 @default.
• W2128517665 countsByYear W21285176652021 @default.
• W2128517665 countsByYear W21285176652022 @default.
• W2128517665 countsByYear W21285176652023 @default.
• W2128517665 crossrefType "journal-article" @default.
• W2128517665 hasAuthorship W2128517665A5053803963 @default.
• W2128517665 hasAuthorship W2128517665A5057335320 @default.
• W2128517665 hasAuthorship W2128517665A5060247604 @default.
• W2128517665 hasAuthorship W2128517665A5075196043 @default.
• W2128517665 hasAuthorship W2128517665A5077855569 @default.
• W2128517665 hasAuthorship W2128517665A5083044716 @default.
• W2128517665 hasAuthorship W2128517665A5083314956 @default.
• W2128517665 hasBestOaLocation W21285176651 @default.
• W2128517665 hasConcept C126322002 @default.
• W2128517665 hasConcept C141071460 @default.
• W2128517665 hasConcept C17991360 @default.
• W2128517665 hasConcept C198451711 @default.
• W2128517665 hasConcept C2777077863 @default.
• W2128517665 hasConcept C2777138892 @default.
• W2128517665 hasConcept C2777226972 @default.
• W2128517665 hasConcept C2777575956 @default.
• W2128517665 hasConcept C2779722408 @default.

• next